Clinical Trial Update: Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study [Phase 3]

View source ↗

Summary

A Phase 3 Pragmatica-Lung study compares ramucirumab plus pembrolizumab versus usual care for stage IV or recurrent non-small cell lung cancer after prior immun…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• Ramucirumab (ramucirumab)

Snippet

Sponsor: SWOG Cancer Research Network | Conditions: Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 | Phase 3 | Status: ACTIVE_NOT_RECRUITING